| I-043 Nils Bundgaard Model informed dose projection for SAB-176 using a joint time-to-event modeling approach in high-risk (HR) patients infected with Influenza Wednesday 10:20-11:50 |
| I-044 Nils Bundgaard Framework for Polyclonal Antibody Drug Development: Integrating Trial Data and Literature Models Wednesday 10:20-11:50 |
| I-045 Nils Bundgaard Characterization of the population dose-exposure-efficacy relationships of vamorolone, a synthetic corticosteroid drug in the treatment of Duchenne Muscular Dystrophy (DMD) Wednesday 10:20-11:50 |
